Journal article
Interpreting and implementing the 2018 pain, agitation/sedation, delirium, immobility, and sleep disruption clinical practice guideline
MC Balas, GL Weinhouse, L Denehy, G Chanques, B Rochwerg, CJ Misak, Y Skrobik, JW Devlin, GL Fraser
Critical Care Medicine | LIPPINCOTT WILLIAMS & WILKINS | Published : 2018
Abstract
The 2018 Clinical Practice Guideline for the Prevention and Management of Pain, Agitation (Sedation), Delirium, Immobility, and Sleep (Disruption) (PADIS) in adult patients in the ICU addresses new management challenges related to pain, agitation, and delirium and offers guidance on two additional topics rehabilitation/mobility and sleep (1, 2). The PADIS guidelines build on the 2013 Society of Critical Care Medicine (SCCM) PAD guidelines (3) and incorporate a number of methodological innovations, including critical illness survivor input from start to finish (4 6). The PADIS methods, with an emphasis on those approaches that are novel, are outlined in a separate methods article (7).
Grants
Funding Acknowledgements
Dr. Balas received funding from Select Medical (primary investigator on research study exploring Assess, Prevent, and Manage Pain, Both Spontaneous Awakening Trials and Spontaneous Breathing Trials, Choice of analgesia and sedation, Delirium: Assess, Prevent, and Manage, Early mobility and Exercise, and Family engagement and empowerment bundle adoption). Dr. Denehy participates in the Australian Physiotherapy Association. Dr. Chanques participates in other healthcare professional organization activities. Dr. Rochwerg participates as a guideline methodologist for other organizations (i.e., American Thoracic Society [ATS] and Canadian Blood Service) in addition to Society of Critical Care Medicine. Dr. Skrobik participates in the ATS and the American College of Chest Physicians, and she is on the editorial board for Intensive Care Medicine and Chest. Dr. Devlin has received research funding from the National Institute of Aging, National Heart, Lung and Blood Institute, and AstraZeneca Pharmaceuticals; is on the editorial board of Critical Care Medicine; and is the president of the American Delirium Society. The remaining authors have disclosed that they do not have any potential conflicts of interest.